Biopharmaceutical company
Inflation Reduction Act of 2022 (PL 117-169) - creating Medicare negotiation of drugs, creating a new inflation rebate under Medicare, limiting insulin copays to $35/month, capping Medicare Part D premium growth, expanding premium and co-pay assistance on prescription drugs for low-income individuals, and capping Medicare out of pocket costs at $2,000 per year. , and preventing commercial spillover of maximum fair price into markets beyond Medicare; Value of prescription drugs; Issues related to patient assistance programs and copay accumulators; Issues related to 340b Drug Pricing Program; Issues related to Medicare Part D; Issues related to Medicare Part B; Education around innovative therapies in dermatology; S. 3700/H.R. 6833, Affordable Insulin Now Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation; Issues related to the Public Health Emergency; Issues related to the White House Cancer Moonshot initiative; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
AVENUE SOLUTIONS
401 9th St. NW, Suite 720, Washington, DC, 20004, US
TRACY SPICER ELIZABETH MACDONALD BARNETT